

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Joan T. Gewirtz
Serial No.: 10/670056
Filed: September 24, 2003
For: Cosmetic Composition

Mail Stop Non Fee
Amendment
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

February 21, 2004

Preliminary Amendment

The following amendment is being proffered prior to any action on the application. Kindly enter the following:

Please add a new final page to the application (following the last paragraph on page 12)

Other compounds that may be used in place of Latanoprost or in combination therewith include Lumigan (Bimatoprost).


Lumigan, like Latanoprost or Xalactan is a prostaglandin F₂₀₁ analogue. It is effective in the same manner as Latanoprost, i.e., it too is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure by increasing the outflow of aqueous humor. It has been established that the main mechanism of action is increased uveoscleral outflow.

In some subjects Lumigan, like Xalactan (Latanoprost) may cause a gradual change in eye color by increasing the amount of brown pigment in the iris and periorbital tissue (eyelid) and increased pigmentation and growth of eyelashes.

Lumigan is formulated in the same manner as Latanoprost, in the same amounts, for topical administration to the lash line as a cosmetic including mascara formulation.

It is respectfully requested that the Preliminary Amendment be entered and considered together with the application.

Respectfully submitted,


Evelyn M. Sommer
Registration No. 19,603
Attorney for Applicant
825 Third Avenue 30th Floor
New York, New York 10022
212-527-2657

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the 76 day of Feb, 2004

